Psychiatr. praxi 2017; 18(2): 56-58 | DOI: 10.36290/psy.2017.010

Current and potential pharmaceutical possibilities in PTSD treatment

MUDr. Petra Havlíková
Psychiatrická nemocnice Šternberk

Posttraumatic stress disorder (PTSD) is a prolonged or delayed response of an individual to life-threatening situations. The disease often

has a chronic progression and negatively affects the quality of the patients’ life. The article offers a review of currently used psychopharmaceuticals

as well as potentially potent pharmaceuticals, which has not been recommended in clinical practice so far. Psychotherapeutic

approaches that form an integral part of PTSD therapy go beyond the overview and attention to them will be paid elsewhere.

Keywords: PTSD, treatment, antidepressants, mood stabilizers, antipsychotics, propranolol, hydrocortisone, MDMA, D-cycloserine, alpha 2 Adrenergic Receptor Agonists

Published: July 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Havlíková P. Current and potential pharmaceutical possibilities in PTSD treatment. Psychiatr. praxi. 2017;18(2):56-58. doi: 10.36290/psy.2017.010.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ditlevsen DN, Elklit A. Gender, trauma type, and PTSD prevalence: a re-analysis of 18 nordic convenience samples. Annals of General Psychiatry 2012; 11: 26. Go to original source... Go to PubMed...
    2. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for posttraumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006; (1)25:CD002795. Go to original source...
    3. Jeffreys M. Clinician's guide to medications for PTSD. National Center for PTSD. US Department of Veterana Affairs 2009.
    4. Falcon S, Ryan C, Chamberlain K, Curtis G. Tricyclics: possible treatment for posttraumatic stress disorder. J Clin Psychiatry 1985; (9)46: 385-388.
    5. Davidson JR, Kudler H, Smith R, Mahorney SL, Lipper S, Hammett E. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry 1990; (3)47: 259-266. Go to original source... Go to PubMed...
    6. Reist C, Kauffmann CD, Haier RJ, Sangdahl C, DeMet EM, Chicz-DeMet A. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry 1989; (4)146: 513-516. Go to original source... Go to PubMed...
    7. Pivac, Kozarić-Kovacić D. Pharmacotherapy of treatment-resistant combat-related posttraumatic stress disorder with psychotic features. Croat Med J 2006; (3)47: 440-451.
    8. Ahearn, Juergens T, Cordes T, Becker T, Krahn D. A review of atypical antipsychotic medications for posttraumatic stress disorder. Int Clin Psychopharmacol 2011; (4)26: 193-200. Go to original source... Go to PubMed...
    9. Wang HR, Woo YS, Bahk WM. Atypical antipsychotics in the treatment of posttraumatic stress disorder. Clin Neuropharmacol 2013; (6)36: 216-222. Go to original source... Go to PubMed...
    10. Pilkinton P, Berry C, Norrholm S, Bartolucci A, Birur B, Davis LL. An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder. Psychopharmacol Bull 2016; (2)46: 8-17.
    11. Lipper S, Davidson JRT, Grady TA. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; (12)27: 849-854. Go to original source... Go to PubMed...
    12. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; (9)52: 361-364.
    13. Hammer MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13: 141-146. Go to original source... Go to PubMed...
    14. Hertzberg MA, Butterfield MI, Feldman ME. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; (9)45: 1226-1229. Go to original source... Go to PubMed...
    15. Gupta MA, Knapp K. Lithium carbonate decreases acute suicidality in posttraumatic stress disorder. Aust N Z J Psychiatry 2013; (12)47: 1217. Go to original source... Go to PubMed...
    16. Prasko J, Latalova K, Grambal A, Kamaradova D. Off-Label Use of Second Generation Antipsychotics in Anxiety Disorders and Obsessive Compulsive Disorder. Act Nerv Super Rediviva 2010; 52: 229-240.
    17. Heim C, Nemeroff CB. Neurobiology of posttraumatic stress disorder. CNS Spectr 2009; 14: 13-24. Go to original source...
    18. McGhee L, Maani Ch, Garza T, Gaylord K, Black I. The Correlation Between Ketamine and Posttraumatic Stress Disorder in Burned Service Members 2007; 10: 1097.
    19. Soeter M, Kindt M. High Trait Anxiety: A Challenge for Disrupting Fear Memory Reconsolidation 2013; 10: 1371. Go to original source...
    20. Koola M, Varghese S, Fawcett J. High-dose prazosin for the treatment of post-traumatic stress disorder. Ther Adv Psychopharmacol 2014; (1)4: 43-47. Go to original source... Go to PubMed...
    21. Detweiler MB, Pagadala B, Candelario J, Boyle JS, Detweiler JG, Lutgens BW. Treatment of Post-Traumatic Stress Disorder Nightmares at a Veterans Affairs Medical Center. J Clin Med 2016; (12)5: 10.3390. Go to original source... Go to PubMed...
    22. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 2008; (12)63: 1118-1126. Go to original source... Go to PubMed...
    23. Kushner M, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB. D-Cycloserine augmented exposure therapy for obsessive compulsive disorder. Biol Psychiatry 2007; 62: 835-838. Go to original source... Go to PubMed...
    24. Mills L, Teesson M, Ross J, Peters L. Trauma, PTSD, and substance use disorders: Findings from the Australian National Survey of Mental Health and Well-Being. American Journal of Psychiatry 2006; (4)163: 652-658. Go to original source...
    25. Johansen P, Krebs T. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J. Psychopharmacol 2009; 23: 389-391. Go to original source... Go to PubMed...
    26. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. Physiological and subjective responses to controlled oral 3, 4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 2008; 28: 432-440. Go to original source... Go to PubMed...
    27. Aerni A, Traber R, Hock C, Roozendaal B, Schelling G, Papassotiropoulos A, Nitsch RM, Schnyder U, de Quervain DJ. Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 2004; 161: 1488-1490. Go to original source... Go to PubMed...
    28. de Quervain DJ-F. Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci 2011; 108: 6621-6625. Go to original source... Go to PubMed...
    29. Brunet A, Poundja J, Tremblay J, Bui E, Thomas E, Orr S. P. Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: three open-label trials. Journal of Clinical Psychopharmacology 2011; (4)31: 547-550. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.